Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention.

J Cell Physiol 2018 09 16;233(9):6408-6417. Epub 2018 Apr 16.

Department of Chemistry, College of Arts and Sciences, University of Vermont, Burlington, Vermont.

Prostate cancer is screened by testing circulating levels of the prostate-specific antigen (PSA) biomarker, monitoring changes over time, or a digital rectal exam. Abnormal results often lead to prostate biopsy. Prostate cancer positive patients are stratified into very low-risk, low-risk, intermediate-risk, and high-risk, based on clinical classification parameters, to assess therapy options. However, there remains a gap in our knowledge and a compelling need for improved risk stratification to inform clinical decisions and reduce both over-diagnosis and over-treatment. Further, current strategies for clinical intervention do not distinguish clinically aggressive prostate cancer from indolent disease. This mini-review takes advantage of a large number of functionally characterized microRNAs (miRNA), epigenetic regulators of prostate cancer, that define prostate cancer cell activity, tumor stage, and circulate as biomarkers to monitor disease progression. Nanoparticles provide an effective platform for targeted delivery of miRNA inhibitors or mimics specifically to prostate tumor cells to inhibit cancer progression. Several prostate-specific transmembrane proteins expressed at elevated levels in prostate tumors are under investigation for targeting therapeutic agents to prostate cancer cells. Given that prostate cancer progresses slowly, circulating miRNAs can be monitored to identify tumor progression in indolent disease, allowing identification of miRNAs for nanoparticle intervention before the crucial point of transition to aggressive disease. Here, we describe clinically significant and non-invasive intervention nanoparticle strategies being used in clinical trials for drug and nucleic acid delivery. The advantages of mesoporous silica-based nanoparticles and a number of candidate miRNAs for inhibition of prostate cancer are discussed.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.26593DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5993634PMC
September 2018
4 Reads

Publication Analysis

Top Keywords

prostate cancer
36
prostate
12
cancer
11
indolent disease
8
strategies clinical
8
provide effective
4
effective platform
4
targeted delivery
4
delivery mirna
4
platform targeted
4
nanoparticles provide
4
monitor disease
4
biomarkers monitor
4
disease progression
4
progression nanoparticles
4
mirna inhibitors
4
circulate biomarkers
4
prostate tumor
4
progression prostate-specific
4
prostate-specific transmembrane
4

References

(Supplied by CrossRef)
Nanoparticles in the clinic
Anselmo et al.
Bioengineering & Translational Medicine 2016
Molecular pathways: microRNAs, cancer cells, and microenvironment
Berindan-Neagoe et al.
Clinical Cancer Research 2014
Circulating miRNAs are correlated with tumor progression in prostate cancer
Brase et al.
International Journal of Cancer Journal International Du Cancer 2011
MicroRNAs in the control of metastatic bone disease
Browne et al.
Trends in Endocrinology and Metabolism 2014

Similar Publications